180 Life Sciences Corp. (ATNF): Price and Financial Metrics


180 Life Sciences Corp. (ATNF): $3.33

0.03 (+0.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATNF to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ATNF Stock Price Chart Interactive Chart >

Price chart for ATNF

ATNF Price/Volume Stats

Current price $3.33 52-week high $71.40
Prev. close $3.30 52-week low $1.18
Day low $3.25 Volume 193,767
Day high $3.40 Avg. volume 6,579,993
50-day MA $5.08 Dividend yield N/A
200-day MA $16.37 Market Cap 6.74M

180 Life Sciences Corp. (ATNF) Company Bio


180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.


ATNF Latest News Stream


Event/Time News Detail
Loading, please wait...

ATNF Latest Social Stream


Loading social stream, please wait...

View Full ATNF Social Stream

Latest ATNF News From Around the Web

Below are the latest news stories about 180 LIFE SCIENCES CORP that investors may wish to consider to help them evaluate ATNF as an investment opportunity.

180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease

PALO ALTO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Treatments for early stage Dupuytren’s disease: an evidence-based approach’ in The Journal of Hand Surgery (European Volume). In the publication, Professor Jagdeep Nanchahal, chairman of the medical advisory board of 180 Life Sciences, and his colleague at the University of Oxford, describe the limitations for th

Yahoo | January 25, 2023

180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom

PALO ALTO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company has engaged Kinexum, a strategic advisory firm, to support the Company in submitting a Marketing Authorisation Application (MAA) for adalimumab to treat progressive early-stage Dupuytren’s disease. The MAA will be submitted to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA or Agency). As part of the ap

Yahoo | January 17, 2023

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

PALO ALTO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on January 4, 2023 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”). As indicated in the letter, Nasdaq determined that for 1

Yahoo | January 5, 2023

180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease

PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Dupuytren’s disease: a localized and accessible human fibrotic disorder’ in the journal Trends in Molecular Medicine. In the article, the authors at the University of Oxford, led by Professor Jagdeep Nanchahal, chairman of the medical advisory board of 180 Life Sciences, describe the biology of Dupuytren’s diseas

Yahoo | January 4, 2023

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

PALO ALTO, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Dear Fellow Shareholder, As we come to the end of 2022, I am pleased to provide an update for our shareholders. In keeping with good corporate practice and US Securities and Exchange Commission (SEC) regulations, we have refrained from answering individual queries from shareholders until we were able to provide information to all shareholders at the same time. Our priorities continue to be our clinical programs, repurposing anti-Tumor Necrosis

Yahoo | December 29, 2022

Read More 'ATNF' Stories Here

ATNF Price Returns

1-mo -1.77%
3-mo -60.43%
6-mo -86.99%
1-year -94.18%
3-year -98.45%
5-year N/A
YTD -1.77%
2022 -95.65%
2021 42.86%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7424 seconds.